One platform connecting startups, corporations, research institutions, regions and investors
Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE
1. Technology overview
Lumos Diagnostics develops, manufactures and distributes point-of-care diagnostic technologies and is listed on the ASX (LDX). Its site also lists services for assay development, readers, app and cloud, manufacturing and regulatory affairs for third parties.
FebriDx is a rapid all-in-one test device for aiding diagnosis of acute respiratory infection. It uses a fingerstick blood sample and dual biomarker technology to help separate bacterial from viral infection, returns a result in about 10 minutes and needs no instrument.
2. Highlighted features & specifications
- Fingerstick sample: capillary blood collection without a lab draw.
- Dual biomarker test: helps distinguish bacterial from non-bacterial infection.
- Fast result: about 10 minutes.
- Instrument-free format: all-in-one disposable device.
- Contract services: assay development and manufacturing for third parties.
- Digital readers: reader, app and cloud services listed for partner tests.
3. Potential application
Private clinic chains can triage respiratory patients before prescribing antibiotics. Urgent care and occupational health centers can screen workers quickly. Distributors can pair FebriDx with a connected reader for outbreak monitoring.
4. Benefits
Results in about 10 minutes from a fingerstick sample support faster triage in clinics. The site cites a 99 percent negative predictive value for ruling out bacterial infection. Guiding antibiotic decisions can reduce unnecessary prescriptions. No analyzer is needed.
5. Market trends & opportunities
Point-of-care tests for acute respiratory infection support antibiotic stewardship, a priority as antimicrobial resistance rises. Vietnam has high antibiotic use in primary care, so rapid tests that separate bacterial from viral illness have a clear fit in clinics and pharmacies, subject to local registration.
6. Other information
ASX-listed (LDX). 2026 news on its site includes US FDA 510(k) clearance with CLIA waiver (2026-03), a BARDA-funded paediatric study reaching 250 patients (2026-05) and a three-year contract manufacturing agreement with Micro-Pak (2026-04). Headquarters and founding year not stated on fetched pages.
